Health News Releases

  • Today July 1
Rachel Nordberg, PhD, from the DELTAi Lab at UC Irvine, prepping the BioServe device before it goes
June 30, 13:50
Cartilage Tissue Engineering Heads to Orbit in NSF and NASA-supported Study at the International Space Station
Researchers in the DELTAi Lab at the University of California, Irvine (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsites.uci.edu%2Fdeltai%2F&esheet=54561327&newsitemid=2026062954
June 29, 09:34
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion followin
Burjeel Holdings’ inaugural Sukuk was priced at a 7.000 % profit rate and a yield of 7.125% (Photo:
June 28, 14:55
Burjeel Holdings Prices First MENA Healthcare Sukuk Since 2018, 3.2x Oversubscribed
The offering attracted significant demand from high-quality international and regional investors, with the orderbook peaking at USD 1.6 billion, representing 3.2x oversubscription. The strength of the
June 26, 11:30
MRM Health Strengthens Board with Michel Detheux as Chairman and Hans-Jürgen Wörle as Independent Director as MH002 Advances Through Phase 2b
MRM Health, a clinical-stage biotech developing microbiome-based therapies for immune-mediated diseases, today announced the appointment of two experienced industry leaders to its Board of Directors a
June 24, 16:32
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&eshee
June 24, 08:51
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundati
June 23, 11:30
HistoSonics Announces Financing with Participation from Yosemite Among Other Strategic Investors
HistoSonics (https://histosonics.com/?utm_source=chatgpt.com), the developer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the closing of a new financing r
Cytiva × CellFiber | Next-Generation Stem Cell Manufacturing & Commercialization Strategy Workshop
June 22, 14:00
CellFiber to Co-Host Next-Generation Stem Cell Manufacturing and Commercialization Workshop with Cytiva in Korea
CellFiber will jointly host the Next-Generation Stem Cell Manufacturing and Commercialization Strategy Workshop with Cytiva on Wednesday, 15 July 2026 at the Cytiva APAC Fast Trak™ Center in Songdo, I
June 19, 11:01
Astrogen, inc. Validates Autism Spectrum Disorder Research with Prestigious Folia Award
Astrogen, inc. (https://astrogen.co.kr/eng/index.html), a leading biotech company in South Korea, said that it has received the “Folia Award (https://onlinelibrary.wiley.com/doi/toc/10.1111/) (ISSN)14
June 17, 15:55
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chro
Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Dru
June 17, 11:30
Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery
Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in labora
June 16, 16:55
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54552126&newsitemid=20260615651327&lan=en-US&ancho
June 16, 08:55
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (
Syngenta Country Head for France Anne Azam (2nd from right) with India’s Minister of Commerce and In
June 15, 16:45
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI
India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the
June 15, 11:10
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 E
Visit Roquette at booth E3D26 to meet with its team of experts
June 12, 16:50
Roquette Showcases Scalable Drug Delivery Innovations at CPHI China 2026
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, will showcase its comprehensive portfolio of innovative drug delivery solutions at CPHI & PMEC China 2026, taking pl
June 12, 15:20
Parse Biosciences Launches the Next Generation of its Immune Profiling Kits
Parse Biosciences (https://www.parsebiosciences.com/), the leading provider of scalable and accessible single cell sequencing solutions, today launched the next generation of its Evercode™ TCR (https:
June 12, 15:10
Merrithew® Expands Global Mindful Movement Leadership with Acquisition of the GYROTONIC® Organization
Merrithew®, a global leader in mindful movement education and equipment and creator of internationally recognized programs including STOTT PILATES®, ZEN·GA®, Halo® Training and Total Barre®, today ann
June 12, 11:20
Cosylab and Heron Neutron Medical Corp. Sign Letter of Intent to Advance Global Deployment of Accelerator-Based BNCT Systems
Cosylab and Heron Neutron Medical Corp. announced today, 10 June 2026, the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deploymen
June 12, 10:51
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279),
June 11, 14:45
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments
Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China - the largest of its kind - exploring the
Cover of the June 2026 issue of Crystal Growth & Design, featuring this research.
June 10, 16:45
New Polymorph of Indomethacin Discovered
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced tha
Oral-B iO9 Black
June 10, 15:00
New Study Reveals the True Environmental Impact of Periodontal Disease - And What You Can Do About It
Today P&G Oral Care announces the release of a new, first-of-its kind LCA study published in the Journal of Dentistry finds managing advanced periodontal disease can be associated with up to ~10× high
June 10, 15:00
Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercialization
Neuraptive Therapeutics today announced the appointment of Ulf Wiinberg to its Board of Directors and William “Bill” MacKenzie as Senior Vice President - Finance. Mr. Wiinberg is a seasoned biotech
June 10, 14:00
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeuti
June 10, 12:00
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities
Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its
June 09, 17:45
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workf
June 09, 13:30
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small caps
June 05, 11:30
New Evidence Offers Hope for Ketogenic Therapy in Treatment of Anorexia Nervosa
A pilot study published today in Communications Medicine (https://www.nature.com/articles/s43856-026-01644-0) demonstrates the potential of a new approach to treating anorexia nervosa — a disorder for
June 03, 13:00
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54545081&newsitemid=20260601948824&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
June 01, 15:35
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the
May 31, 12:25
Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study
Rubedo Life Sciences, Inc. (https://www.rubedolife.com/) (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced prel
May 31, 11:43
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (t
May 31, 11:40
AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine
The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Cure
May 29, 12:00
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England J
May 29, 10:00
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)
Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) (https://www.fda.gov/) has a
Parse Biosciences and bit.bio Announce Landmark Alliance
May 28, 14:00
Parse Biosciences and bit.bio Announce Landmark Alliance
Parse Biosciences (https://www.parsebiosciences.com/), the leading provider of scalable and accessible single cell sequencing solutions, today announced an alliance with bit.bio (https://www.bit.bio/)
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discov
May 27, 17:10
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated librar
May 27, 16:30
Mevion Medical Systems and Tam Anh General Hospital Partner to Bring Advanced Proton Therapy to Vietnam
Mevion Medical Systems has signed a definitive purchase agreement to bring the MEVION S250-FIT Proton Therapy System™ to Tam Anh General Hospital in Vietnam. This would be the first proton therapy sys
May 26, 16:00
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and s
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly
May 25, 14:15
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning s
May 25, 13:55
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-
Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psy
May 25, 13:15
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patien
The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch
May 25, 13:10
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1
May 22, 15:30
HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion
HistoSonics (https://histosonics.com/), the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has received approval from the Taiwan Food and Drug A
May 22, 09:51
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nomin
BeOne Medicines' One Save Changes Everything campaign uses soccer as a lens to recognize the scient
May 21, 15:30
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
BeOne Medicines Ltd. (https://beonemedicines.com/) (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything (https://beonemedicines.com/
Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; ai
May 21, 08:35
Chiesi Group Announces New Chair and Vice Chair
Chiesi today announced a planned leadership change in its Board of Directors: Maria Paola Chiesi has been appointed Chair of the Board, succeeding Alessandro Chiesi, who is completing his tenure after
May 20, 16:40
InterSystems IntelliCare Becomes the First AI-Native EHR to Achieve EU Medical Device Regulation Certification
InterSystems (https://www.intersystems.com/), a creative data technology provider powering more than one billion health records globally, today announced that its electronic health record (EHR) soluti
May 20, 11:35
Samsung Bioepis Launches Ustekinumab Biosimilar, Marking Its First Product Launch in Japan
Samsung Bioepis Co., Ltd. today announced the launch of Ustekinumab BS 45 mg Syringe for S.C. Injection ‘NIPRO’, a biosimilar referencing Stelara[1] (ustekinumab), marking its first product launch in
May 20, 10:40
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy
Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim re
May 19, 16:00
Organon to Present New Research on Access and Value at ISPOR 2026
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatolog
May 17, 11:55
Medisca and dsm-firmenich Partner to Expand Access to Pharmaceutical-Grade Vitamin APIs for U.S. Compounding Market
Medisca, a global leader in personalized pharmaceutical medicine, has entered into a strategic partnership with dsm-firmenich, a leading ingredient manufacturer serving regulated pharmaceutical market
Charles River and MEDIPOST signed non-exclusive Memorandum of Understanding (MOU) to collaborate on
May 17, 11:00
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well
BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton W
May 15, 15:30
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
BeOne Medicines Ltd. (https://beonemedicines.com/) (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has gr
Aster Guardians Global Nursing Awards 2026 - Top 10 Finalists (Photo: AETOSWire)
May 15, 11:30
Aster Guardians Global Nursing Award Announces Top 10 Finalists for 2026
On the occasion of International Nurses Day, Aster DM Healthcare has announced the Top 10 finalists for the fifth edition of the Aster Guardians Global Nursing Award 2026, selected from over 134,000 r
Signing ceremony with imec held on April 9
May 14, 10:10
Rigaku Accelerates Next-generation Semiconductor Metrology Development Leveraging World-Class Research Infrastructure
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced the
May 14, 09:30
Angelalign Technology Inc. (6699.HK) Applauds European Court Rejection of Patent Infringement Claim
Angelalign Technology Inc. (6699.HK) (“Angel”) (http://www.angelaligner.com) today said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by A
Oral B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability Focused Oral Hea
May 13, 16:26
Oral‑B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability‑Focused Oral Health Studies
Oral B today announces The Big Rethink 2026, the next evolution of its flagship oral health inclusion programme, developed in partnership with the International Association for Disability and Oral Hea
May 13, 16:11
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54533184&newsitemid=20260510786927&lan=en-US&anc
May 12, 14:30
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking
May 12, 10:15
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulatio
Urethral stricture starts with narrowing of a short segment of urethral lumen. At early stages, it i
May 11, 16:50
Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 2026
A path breaking scientific discovery, unraveling successful wound healing mechanism in urethral stricture with BEES-HAUS (https://www.ncrm.org/myth/beeshaus/) cell therapy has been reported by Indo-Ja
May 10, 15:25
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of
WHOOP Expands Health Platform with On-Demand Clinician Access and New AI Features
May 10, 13:30
WHOOP Expands Health Platform with On-Demand Clinician Access and New AI Features
WHOOP (https://www.whoop.com/kr/en/?utm_source=PR&utm_medium=PR&utm_campaign=SR_A), the human performance company, today announced a new suite of health and AI-driven enhancements and feature updates
HE Mansoor Al Mansoori (Left) and Tom Hale (Right)
May 08, 16:50
Department of Health - Abu Dhabi and ŌURA Partner to Advance Preventive Health in Abu Dhabi
Department of Health—Abu Dhabi (https://www.doh.gov.ae/en/) (DoH) and ŌURA (https://ouraring.com/ko?srsltid=AfmBOormyEZs4LuQCQfSGbmxbAuvAy4qBM3q7akrgnjiPIzDNqS2nZh9), maker of the world’s leading smar
May 06, 16:25
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), m
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Mo
May 04, 16:00
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Wid
May 03, 17:20
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership
CorFlow Therapeutics AG (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.corflow.com&esheet=54526078&newsitemid=20260430413675&lan=en-US&anchor=CorFlow+Therapeutics+AG&index=1&md5
May 03, 16:00
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis
MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH
May 03, 11:40
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation
SS&C Technologies Holdings, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ssctech.com%2F%3Futm_campaign%3DSSC2026-Enterprise-Press-Release-0426%26utm_medium%3Dpressreleas
May 03, 11:00
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54524717&newsitemid=20260429582815&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
May 03, 10:40
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal
David Weinreich, Global Head of R&D and Chief Medical Officer
May 03, 10:20
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481 (https://cts.businesswire.com/ct/CT?id=smartlink&url=h
Masimo RD SET® Neo Pulse Oximetry Sensor
April 30, 16:10
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study
Masimo (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54524005&newsitemid=20260428136753&lan=en-US&anchor=Masimo&index=1&md5=9061676d45e4b2fdccbe6887499605e3)
Dr. Vivek Mundada with Medcare multidisciplinary medical team (Photo: AETOSWire)
April 30, 09:40
Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US
Medcare Royal Speciality Hospital (MRSH) in Dubai has become the world’s first hospital outside the USA, to offer a newly licensed intrathecal gene therapy - Itvisma, to adult patients with Spinal Mus
Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equi
April 30, 08:55
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), today announced that the compan
Credits to Roquette
April 29, 17:15
Roquette Showcases Its Expanded Consumer Healthcare Capabilities at Vitafoods Europe 2026
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will present its expanded portfolio at Vitafoods Europe 2026 which is taking place from May 5 to May 7 in
April 29, 13:13
Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific
Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as “ATLATL”), global innovation platform for life science research and development, today announced that the companies h
PCI Pharma Services announced a series of major infrastructure investments that substantially deepen
April 28, 16:00
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities
PCI Pharma Services (“PCI”) - a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies - announced a ser
April 28, 15:40
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adu
Sun Pharma signs Definitive Agreement to Acquire Organon
April 28, 15:30
Sun Pharma signs Definitive Agreement to Acquire Organon
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (N
Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt
April 27, 15:20
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health
Today, the Higher Regional Court of Frankfurt upheld the February 2025[1] partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia
First-in-human contrast enhanced MRI images with GE HealthCare’s mangaciclanol
April 24, 13:51
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents
GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI)
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
April 24, 11:10
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Agenus (https://www.agenusbio.com/) Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma (https://bappharma.com/), a global medicines access and clinical trial supply company, t
April 23, 16:33
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. · Strong start to the year delivering net sales of 1,47
April 23, 15:51
Galderma Shareholders Approve All Annual General Meeting Proposals
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), h
April 23, 15:00
Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Turbine, a leading virtual biology company, to advance tra
Double Logo
April 22, 11:10
Rigaku Enters Strategic Alliance with Onto Innovation through 27 % Equity Investment
Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), a global leader in X-ray analytical technologies, today announced that it has entered into a str
PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bi
April 21, 15:30
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys
SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with San
April 21, 10:15
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced t
Electron microscope image of BK virus, showing the VP1 capsid protein that creates an icosahedral sh
April 20, 09:35
Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program
Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first
April 19, 14:55
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-dr
Figure 1: Pincushion plant (Diapensia lapponica) in bloom, growing in alpine rocky areas. Its distri
April 17, 15:30
New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample
Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President
April 16, 15:30
Invivoscribe Announces the PrepQuant™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows
Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the PrepQuant™ System, a novel sample preparation platform that int
April 16, 14:19
Ferring Pharmaceuticals and Gallup Announce Landmark Global Public Attitudes Study on Fertility and Family-Building
Ferring Pharmaceuticals and Gallup today announced the Ferring Global Fertility Monitor, a global study on the factors influencing people’s fertility choices, at the 2026 Annual Convening of Semafor W
April 16, 14:12
Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based reg
April 15, 08:40
Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate
Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nec
IFF showcases wellness innovation for beauty.
April 14, 10:00
IFF Explores the Science Behind Well-Being at In‑Cosmetics Global 2026
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients and health & biosciences—will showcase scent and bioscience innovations focused on wellness and sustainability at In‑Cosmetics
Clean Cells and Naobios Showcase Complete End-to-End Viral Vaccines and Vector Solutions at Bio Kore
April 13, 11:00
Clean Cells and Naobios Showcase Complete End-to-End Viral Vaccines and Vector Solutions at Bio Korea 2026
Clean Cells (https://clean-cells.com/), a leading biopharmaceutical quality control services provider specializing in biologics GMP testing, and Naobios (https://www.naobios.com/), a CDMO (Contract De
25 per page50 per page75 per page100 per page